Clinical Trials Browser

Observational × atezolizumab × Gastrointestinal × Clear all

Unresectable Hepatocellular Carcinoma

NCT07284121 2026-03-27

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Recruiting

700 enrolled

GastrointestinalThoracic

Carcinoma, Hepatocellular, Lung Neoplasms

NCT03782207 2026-01-08

IMreal

Active not recruiting

2,756 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT04862949 2025-12-12

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed

131 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05197504 2025-09-05

HCC

Completed

166 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05717738 2024-06-13

CCGLC-008

Recruiting

300 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05173298 2024-02-07

HCC

Unknown

100 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed

1,758 enrolled

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

REFINE-IO

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

IMreal

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

HCC

CCGLC-001

CCGLC-008

HCC

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)